Science News
Discover the news and inspiring materials from the world of biotechnology.
Mabion Biologics at BIO International Convention 2026
Mabion concluded a highly successful week at the BIO International Convention 2026. Our team engaged in a significant volume of productive meetings, successfully establishing new business relationships.
Learn more
MabionCD20 – Unlocking New Opportunities
MabionCD20 is a anti-CD20 monoclonal antibody originally developed as a biosimilar drug. The project is now being reactivated as an innovative drug, shifting away from the crowded biosimilar market. MabionCD20 already has two orphan drug designations with the potential to pursue further ODD opportunities thanks to Oddifact partnership.
Learn more
NMPA approves first bispecific antibody-drug conjugate: a new treatment for nasopharyngeal carcinoma
On June 22, 2026, the NMPA approved iza-bren (izalontamab brengitecan) as the world’s first bispecific antibody-drug conjugate. Developed by Biokin Pharmaceutical, the drug is indicated for adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). The therapeutic simultaneously targets EGFR and HER3 receptors to enhance selectivity and overcome resistance mechanisms. The Phase III clinical trial demonstrated a confirmed objective response rate of 54.6%, more than doubling that of chemotherapy. Treatment with iza-bren nearly doubled median progression-free survival to 8.4 months and reduced the risk of progression or death by 56%.
Learn more
Mabion Biologics at PCI Days 2026
Mabion Biologics at PCI Days 2026 Key Discussions with Technology Partners at PCI Days PCI Days 2026 is the largest trade fair for the pharmaceutical industry in Central and Eastern Europe. Our industry is all about continuous risk and quality management. To stay ahead of technological trends, we are constantly seeking the best solutions for […]
Learn more
2026: The Era of Co-development in Biopharma Industry
If I were to name the year 2026, it would not be the “Year of Artificial Intelligence” or any other label focusing solely on technology. I would call it the year of Co-development – a collaborative approach that redefines how medical innovations reach patients.
Learn more
Mabion Completes Analytical Development Project for WPD401
Mabion has completed the WPD401 analytical development project, delivering a comprehensive package of 20 analytical methods to support the characterization of a next-generation protein–drug conjugate for innovative oncology applications. The successful completion of the WPD401 project strengthens Mabion’s collaboration with WPD Pharmaceuticals and confirms Mabion’s growing expertise in advanced analytics for complex ADC and PDC molecules. By developing an end-to-end analytical package for WPD401, Mabion has established a strong foundation for further co-development with WPD Pharmaceuticals in the field of innovative conjugated oncology therapeutics.
Learn more
Strengthening Strategic Biopharma Partnerships in Brazil: Mabion Visits Bio-Manguinhos and IBMP
In May 2026, our experts traveled to Rio de Janeiro for the International Symposium on Immunobiologicals to strengthen our partnerships and gain a deeper understanding of Brazil’s rapidly growing biotechnology ecosystem.
Learn more
Hantavirus Vaccine Research in Light of 2026 Cases
By May 2026, the Andes hantavirus outbreak linked to the MV Hondius had left three people dead, others hospitalized across continents, and passengers from 23 countries swept into quarantine, repatriation, and weeks of anxious self-monitoring. The crisis may not signal a pandemic, but its brutal fatality rate, limited treatment options, and absence of a licensed Andes virus vaccine show why hantavirus vaccine development is no longer a distant scientific ambition but an urgent public health necessity.
Learn more
Mabion Biologics at mBank Healthcare Days 2026
Mabion C-suite participated in a meeting with investors and stakeholders during mBank Healthcare Days 2026 in Warsaw. Mabion is engaged in advanced licensing, co-development, and consortium discussions, the results of which will be announced in the H1 2026.
Learn more